Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Thursday 18 July, 2019

Evgen Pharma PLC

Result of AGM

RNS Number : 0310G
Evgen Pharma PLC
18 July 2019
 

 

For immediate release

18 July 2019

 

 

 

 

 

 

Evgen Pharma plc

 ("Evgen" or "the Company")

 

Result of AGM

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, held its Annual General Meeting ("AGM") earlier today at which all resolutions were duly passed.

 

Enquiries:

 

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

 

c/o +44 (0) 20 7466 5000

finnCap

Geoff Nash, Teddy Whiley (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

www.finncap.com

 

+44 (0) 20 7220 0500

WG Partners LLP

Nigel Barnes, Claes Spång

 

+44 (0) 20 3705 9330

Buchanan

Mark Court, Sophie Wills, Tilly Abraham

[email protected]

 

 +44 (0) 20 7466 5000

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGEALXPFLKNEFF

a d v e r t i s e m e n t